tbuckley/cabot-search huggingface dataset:
TCT-87 Non-invasive Renal Denervation Study Using Externally Delivered Focused Ultrasound in Severe Resistant Hypertension: 1 Year Follow up Results
Authors: Roland E. Schmieder, John A. Ormiston, Petr Neuzil, Zdenek Starek, Patrick Kay, Omar Dawood, Thomas Anderson, Michael Gertner, William B. White
Journal: Journal of the American College of Cardiology (2015)
TCT-483 “Real world use of ultra-thin sirolimus-eluting stent with biodegradable polymers. 9-month results from the FLEX-registry.”
Authors: Pedro A. Lemos, Prakash Chandwani, Sudheer Saxena, Padma Kumar Ramachandran, Julio F. Marchini, Micheli Z. Galon, Atul Abhyankar, Puneet Verma, Manjinder Singh Sandhu, Nikhil Parikh, Ashok N. Bhupali, Sharad Jain, Jayesh Prajapati
Journal: Journal of the American College of Cardiology (2015)
TCT-613 Extracranial Carotid And Vertebral Artery Disease And The Risk Of Stroke Following Trans-catheter Aortic Valve Replacement
Authors: Chetan Huded, Quentin Youmans, Jyothy Puthumana, Ranya Sweis, Mark Ricciardi, S.C. Malaisrie, Charles J. Davidson, James Flaherty
Journal: Journal of the American College of Cardiology (2015)
TCT-288 Invasive Coronary Microcirculacion Assessment In Aortic Stenosis: Index Of Microvascular Resistance
Authors: Alejandro Gutierrez-Barrios, Dolores Ruiz-Fernandez, Sergio Gamaza-Chulián, Antonio Agarrado, Jesus Oneto, Javier Benezet
Journal: Journal of the American College of Cardiology (2015)
TCT-225 Impact of Age on the Disruption of Dual Antiplatelet Therapy: Analysis from the PARIS (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented) Patients Registry
Authors: Shunsuke Aoi, Jennifer Yu, Samantha Sartori, Usman Baber, Cono Ariti, Timothy D. Henry, David Cohen, David J. Moliterno, Stuart J. Pocock, C. Michael Gibson, Mitchell Krucoff, George Dangas, Philippe G. Steg, Giora Weisz, Bernhard Witzenbichler, Roxana Mehran
Journal: Journal of the American College of Cardiology (2015)
Effect of kinesins on taxane resistance.
Authors: R. Wesolowski, M. Orloff, E. Downs-Kelly, G. T. Budd, G. R. Stark, S. De, R. R. Tubbs, J. P. Crowe, C. Eng
Journal: Journal of Clinical Oncology (2010)

10545 Background: Over-expression of the kinesins (KIFs) KIFC3, KIFC1, KIF1A, and KIF 5A results in taxane resistance in MDA-MB231 and MDA-MB 468 breast cancer cells. Here we report an exploratory analysis of the association of KIFs and failure to achieve complete pathologic response (pCR) after neo-adjuvant taxane-based chemotherapy for breast cancer. Methods: Microarray expression analysis for kinesin transcript levels was performed on RNA extracted from frozen residual tumor samples of 10 patients with stage IIA-IIIB, HER2 breast cancer who did not achieve pCR after neo-adjuvant taxane-based chemotherapy. Next, we validated our data using expression profiles of 59 tumors from patients treated with a taxane-based neo-adjuvant regimen in EORTC 10994/BIG 00-01 trial by correlating KIF expression with pCR. The public dataset was normalized and vetted prioritized by probes that flank the kinesin gene family. We used Hierarchical Clustering, supervised by Kinesin expression followed by unsupervised clustering on cancer tissues. We calculated the risk associated with docetaxel treatment and failure to achieve pCR for each of the kinesins (R). R>1 signifies expression of a particular KIF associated with achieving pCR. R<1 signifies expression of a particular KIF not associated with achieving pCR. Results: KIF12, KIF3B and KIF5C were significantly over-expressed in the residual tumors of the 10 patients who failed to achieve pCR after paclitaxel exposure (p = 0.021, 0,005, and 0.031, respectively). Conversely, KIF26B was under-expressed (p = 9.56 × 10-7). Our validation study in the public dataset showed that KIF12 and KIF3B over-expression was associated with failure to achieve pCR [R=0.78, p=0.036 and 0.81, p=0.04 respectively] confirming our pilot data. In contrast, over-expression of KIF5C and under-expression of KIF26B were associated with pCR [R of 1.70, p= 0.03 and 1.27, p= 0.025]. In the larger dataset, a new observation, over-expression of KIF14 was associated with a poor response to docetaxel treatment [R=0.037(p=0.005)]. Conclusions: Over-expression of KIF 12 and KIF3B correlated with failure to respond to neo-adjuvant, taxane-containing chemotherapy in the pilot and validation series, suggesting a novel mechanism of taxane resistance. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Amgen, Bristol-Myers Squibb, Genentech, Novartis, Pfizer, sanofi-aventis
Targeted ‘Off-the-Shelf’ Tumor Immunotherapy Using Allogeneic T-Cell Precursors.
Authors: Johannes L. Zakrzewski, David Suh, Odette M. Smith, Christopher King, Gabrielle L. Goldberg, Robert Jenq, Amanda M. Holland, Jeremy Grubin, Sydney X. Lu, Javier Cabrera-Perez, Gabrielle Rizzuto, Derek B. Sant’Angelo, Marcel R.M. van den Brink, John C. Markley, Isabelle Riviere, Michel Sadelain, Juan Carlos Zuniga-Pflucker
Journal: Blood (2007)
Long-term follow-up after chemoradiotherapy (CRT) and surgery in patients (pts) with stage III non-small cell lung cancer (NSCLC): Is bulky mediastinal nodal disease of prognostic importance
Authors: D. J. Adelstein, T. W. Rice, L. A. Rybicki, M. M. Decamp, S. C. Murthy, T. Mekhail, M. A. Carroll
Journal: Journal of Clinical Oncology (2004)

7168 Background: Bulky mediastinal nodal involvement at presentation has been considered a poor prognostic factor in pts with stage III NSCLC. We present long-term follow-up from a phase II trial of accelerated fractionation radiation (AFR), concurrent chemotherapy and surgery, to address this issue. Methods: Between 10/94 and 9/00, 105 pts with surgically proven stage IIIA (N=78) or IIIB (N=27) NSCLC underwent induction treatment consisting of a 96-hour continuous cisplatin infusion (20 mg/m2/day) and a 24-hour infusion of paclitaxel (175 mg/m2) concurrent with AFR (1.5 Gy bid) to a dose of 30 Gy. Surgery was scheduled 4 weeks later, with a second identical course of CRT given 4–6 weeks post-operatively to a total dose of 60–63 Gy. Results: With a median follow-up of 59 (range 35–102) months, the projected Kaplan-Meier (KM) 5-year overall survival is 29%. KM 5-year locoregional and distant control are 85% and 39% respectively. KM 5-year survival was better in clinical stage IIIA vs. IIIB pts (33% vs. 19%, P=0.03); clinical responders to induction vs. non responders (36% vs. 17%, P=0.004); and pathologic responders vs. non-responders (45% vs. 11%, P < 0.001). Pathologic stage after surgery also predicted 5-year survival (stage 0-II: 55%; IIIA: 23%; IIIB - IV: 4%; P < 0.001). Pre-treatment mediastinoscopy identified 20 pts with only microscopic intra-nodal involvement in one or more ipsilateral nodes, and 61 pts with gross macroscopic, but ipsilateral, nodal disease. These two groups did not differ in median or 5-year KM survival (27 vs. 29 months, 45% vs. 27%, P= 0.45). The extent of ipsilateral nodal involvement contributed no prognostic information about survival in a Cox multivariable analysis. Conclusions: Clinical stage IIIA disease, clinical and pathologic response to induction, and a lower pathologic stage are important predictors for survival after this CRT protocol for pts with stage III NSCLC. Bulky ipsilateral mediastinal nodal involvement at diagnosis is of no prognostic importance for survival in these pts and should not be a consideration in treatment planning. No significant financial relationships to disclose.
GW27-e1067 Resveratrol Protects against TNF-α-Induced Injury in Human Umbilical Endothelial Cells through Promoting Sirtuin-1-Induced Repression of NF-KB and p38 MAPK
Authors: Junming Chen, Wei Pan, Huizhen Yu, Shujie Huang, Pengli Zhu
Journal: Journal of the American College of Cardiology (2016)
Genomic Stability: A Novel Function of NF-Kb in Lymphomas.
Authors: Sampath Ramachandiran, Arsene Adone, Xiangxue Guo, Albert Liao, Uston Robert Sunay, Lee Ratner, Haian Fu, Izidore S. Lossos, Harold Saavedra, Leon Bernal-Mizrachi
Journal: Blood (2009)
FCGR Polymorphisms Influence Response to IL2 in Metastatic Renal Cell Carcinoma
Authors: Amy K. Erbe, Wei Wang, Jacob Goldberg, Mikayla Gallenberger, KyungMann Kim, Lakeesha Carmichael, Dustin Hess, Eneida A. Mendonca, Yiqiang Song, Jacquelyn A. Hank, Su-Chun Cheng, Sabina Signoretti, Michael Atkins, Alexander Carlson, James W. Mier, David J. Panka, David F. McDermott, Paul M. Sondel
Journal: Clinical Cancer Research (2016)

Abstract Purpose: Fc-gamma receptors (FCGRs) are expressed on immune cells, bind to antibodies, and trigger antibody-induced cell-mediated antitumor responses when tumor-reactive antibodies are present. The affinity of the FCGR/antibody interaction is variable and dependent upon FCGR polymorphisms. Prior studies of patients with cancer treated with immunotherapy indicate that FCGR polymorphisms can influence antitumor response for certain immunotherapies that act via therapeutically administered mAbs or via endogenous tumor-reactive antibodies induced from tumor antigen vaccines. The previously published “SELECT” trial of high-dose aldesleukin (HD-IL2) for metastatic renal cell carcinoma resulted in an objective response rate of 25%. We evaluated the patients in this SELECT trial to determine whether higher-affinity FCGR polymorphisms are associated with outcome. Experimental Design: SNPs in FCGR2A, FCGR3A, and FCGR2C were analyzed, individually and in combination, for associations between genotype and clinical outcome. Results: When higher-affinity genotypes for FCGR2A, FCGR3A, and FCGR2C were considered together, they were associated with significantly increased tumor shrinkage and prolonged survival in response to HD-IL2. Conclusions: Although associations of higher-affinity FCGR genotype with clinical outcome have been demonstrated with mAb therapy and with idiotype vaccines, to our knowledge, this is the first study to show associations of FCGR genotypes with outcome following HD-IL2 treatment. We hypothesize that endogenous antitumor antibodies may engage immune cells through their FCGRs, and HD-IL2 may enhance antibody-induced tumor destruction, or antibody-enhanced tumor antigen presentation, via augmented activation of innate or adaptive immune responses; this FCGR-mediated immune activity would be augmented through immunologically favorable FCGRs. Clin Cancer Res; 23(9); 2159–68. ©2016 AACR.
Alanine racemase is essential for the growth and interspecies competitiveness of Streptococcus mutans
Authors: Yuan Wei, Wei Qiu, Xue-Dong Zhou, Xin Zheng, Ke-Ke Zhang, Shi-Da Wang, Yu-Qing Li, Lei Cheng, Ji-Yao Li, Xin Xu, Ming-Yun Li
Journal: International Journal of Oral Science (2016)

D-alanine (D-Ala) is an essential amino acid that has a key role in bacterial cell wall synthesis. Alanine racemase (Alr) is a unique enzyme that interconverts L-alanine and D-alanine in most bacteria, making this enzyme a potential target for antimicrobial drug development. Streptococcus mutans is a major causative factor of dental caries. The factors involved in the survival, virulence and interspecies interactions of S. mutans could be exploited as potential targets for caries control. The current study aimed to investigate the physiological role of Alr in S. mutans. We constructed alr mutant strain of S. mutans and evaluated its phenotypic traits and interspecies competitiveness compared with the wild-type strain. We found that alr deletion was lethal to S. mutans. A minimal supplement of D-Ala (150 μg·mL
TCT-663 Anatomic and Procedural Predictors of Paravalvular Leak following Transcatheter Aortic Valve Replacement with a Self-expanding Prosthesis at a High Volume Center Including a Novel Variable of Inflow Expansion
Authors: Nicolas Bettinger, Nadira Hamid, Rebecca Hahn, Susheel Kodali, Torsten P. Vahl, Jonathon M. White, Puja B. Parikh, Isaac George, Martin Leon, Omar K. Khalique
Journal: Journal of the American College of Cardiology (2015)
A Phase I Study of Ibrutinib and Lenalidomide in Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma
Authors: Beth Christian, John Kuruvilla, Sonali Smith, Pierluigi Porcu, Amy S. Ruppert, John C. Byrd, Michael R. Grever, Kristie A. Blum
Journal: Blood (2014)
GW27-e0154 The Experimental Research of BuShenKangShuai Tablets on Adventitia injury induced Carotid Atherosclerosis Formation and Development
Authors: Aiqin Zhong, Shixin Xu, Xin Xiong, Xiaomin Xu, Ying Xin, Ning Zang, Yanyang Li, Yingyu Sie, Guangyin Zhang, Junping Zhang
Journal: Journal of the American College of Cardiology (2016)
Increasing preoperative neutrophil to lymphocyte ratio: An independent predictor of adverse survival after pulmonary resection of non-small cell lung cancer
Authors: K. Sarraf, E. Belcher, E. Raevsky, P. Goldstraw, E. Lim
Journal: Journal of Clinical Oncology (2008)

22090 Background: Increasing neutrophil to lymphocyte ratio (NLR) has been associated with adverse survival after resection of primary or hepatic metastases of colorectal tumors. We aimed to determine the effects of overall white cell, component cell counts and the NLR on stage adjusted survival in patients who subsequently underwent resection for non-small cell lung cancer. Methods: We performed a retrospective review of patients between 1999 and 2005. Data acquisition was via patient medical records and cell counts recorded immediately prior to surgery. Follow-up was by the National Health Service (NHS) database searches and hospital records. Cox proportional hazards regression was used to estimate the impact of NLR on stage adjusted survival. Results: Of 178 patients that underwent pulmonary resection, we excluded 1 patient with CLL. The majority were men 104 (59%) with a mean age of 63 (10) years. In total, 83 were pathologic stage I, 45 stage II, 45 stage III and 4 stage IV. The median follow up time of 29 months, and overall survival was 83% and 54% at 1 and 5 years. In isolation, total white cell count (P=0.99), and neutrophil count (P=0.49), age (P=0.29), cell type (P=0.49) were not significant. On multivariable analysis, increasing NLR (HR 1.10; 1.03–1.17; P=0.004) remained independent prognostic indicator after adjusting for stage. Conclusions: Increasing preoperative NLR is a stage independent predictor of adverse survival in patients undergoing pulmonary resection for primary lung cancer, and may be a useful biomarker in addition to pTNM stage. No significant financial relationships to disclose.
TCT-720 Transfemoral Closure of Mitral paravalvular leak in the presence of metallic aortic valve
Authors: Pilar Jimenez-Quevedo, Luis Nombela-Franco, Corina Biagioni, Guillermo E. Morrison-Polo, Carlos Almería, Barbara Das Neves, Eulogio J. Garcia
Journal: Journal of the American College of Cardiology (2015)
Prosurvival and Chemoprotective Effects of Tumor-Associated Macrophages Reversed By Anti-CSF-1R Monoclonal Antibody in B-Cell Lymphomas
Authors: Anupama Gopisetty, Myriam Foglietta, Min Zhang, Zhiqiang Wang, Nathan Fowler, Richard E. Davis, Sattva S Neelapu
Journal: Blood (2014)
TCT-505 Comparative Clinical Resource Utilization With Bioresorbable Everolimus-eluting Scaffolds Vs. Metallic Everolimus-eluting Stent With Abluminal Polymer In Contemporary Clinical Practice
Authors: Jose M. De la Torre Hernandez, Tamara Garcia Camarero, Dae-Hyun Lee, Fermin Sainz Laso, Silvia Rubio, Ines Toranzo, Luis Ruiz Guerrero, Tania Pino, Gabriela Veiga Fernandez, Javier Zueco
Journal: Journal of the American College of Cardiology (2015)
Double Epigenetic Modulation of High-Dose Chemotherapy (HDC) with Autologous Stem-Cell Transplant (ASCT) for Patients with Refractory or Poor-Risk Relapsed Lymphoma
Authors: Yago Nieto, Benigno C. Valdez, Peter F Thall, Wei Wei, Roy Jones, Chitra M. Hosing, Sairah Ahmed, Uday R. Popat, Elizabeth J. Shpall, Muzaffar Qazilbash, Alison M Gulbis, Paolo Anderlini, Nina Shah, Qaiser Bashir, Amin M. Alousi, Yasuhiro Oki, Fredrick B. Hagemeister, Richard E. Champlin, Borje S. Andersson
Journal: Blood (2015)
Association of serious adverse events with type and sponsorship of clinical trials in patients with lymphoma
Authors: T. L. Koeneke, J. O. Armitage, P. J. Bierman, R. Bociek, J. M. Vose, F. R. Loberiza
Journal: Journal of Clinical Oncology (2007)

6576 Background: Arguments have been made against early phase clinical trials (CTs) as possibly being unethical because its risk may outweigh its potential benefits. Whether this is true in the light of newer biological treatment for cancer is unknown. We therefore examined the association between the incidence of serious adverse events according to type and sponsorship of CTs in pts with lymphoma. Methods: All IRB approved CTs at the University of Nebraska Medical Center from Jan 2000-June 2005 classified as therapeutic for lymphoma involving a biological agent were included. CTs were classified in two ways: by type of CTs (phase I vs II vs III) and sponsorship (Investigator-initiated vs Industry-initiated. Multivariate logistic regression was used to evaluate the association between types/sponsorship of CTs with the incidence of IRB serious adverse events (SAE; no vs yes) and fatal adverse events (FAE; no vs yes) while adjusting for age, sex, race, lymphoma type and stage, interval from dx to tx, co-morbid conditions, and previous tx. Results: 357 pts with lymphoma enrolled in 29 CTs were included. The median age of pt was 54y (21–88). 41% of the pts had follicular lymphoma, 36% diffuse large cell, 14% mantle cell and 9% were other types. 59% had Stage IV lymphoma. 71% of the pts participated in investigator-initiated CTs, while 29% participated in industry-initiated CTs. 21% of pts were enrolled in phase I, 65% in phase II and 14% in phase III studies. SAEs were seen in 49 pts (14%), while FAEs occurred in 13 pts (4%). Multivariate analysis showed the risk of having SAE was independent of the type or sponsor of CTs. Additionally, the risk of FAEs was not associated with the type of CTs. However, the risk of having FAEs was less in investigator- iniatiated CTs than in industry-iniatiated trials (Odds Ratio: 0.13 (95% CI, 0.03–0.61, p = 0.01). Conclusions: Our study showed that in CTs involving biological treatments, the incidence of SAEs was not associated with the type or sponsor of CTs suggesting that use of biological agents in phase I studies may have similar risks to phase II/III trials. Further studies should be done in other types of malignancies to evaluate further the decrease frequency of FAEs seen in investigator-initiated trials. No significant financial relationships to disclose.
Deficiency of base excision repair enzyme NEIL3 drives increased predisposition to autoimmunity
Authors: Michel J. Massaad, Jia Zhou, Daisuke Tsuchimoto, Janet Chou, Haifa Jabara, Erin Janssen, Salomé Glauzy, Brennan G. Olson, Henner Morbach, Toshiro K. Ohsumi, Klaus Schmitz, Markianos Kyriacos, Jennifer Kane, Kumiko Torisu, Yusaku Nakabeppu, Luigi D. Notarangelo, Eliane Chouery, Andre Megarbane, Peter B. Kang, Eman Al-Idrissi, Hasan Aldhekri, Eric Meffre, Masayuki Mizui, George C. Tsokos, John P. Manis, Waleed Al-Herz, Susan S. Wallace, Raif S. Geha
Journal: Journal of Clinical Investigation (2016)

Alterations in the apoptosis of immune cells have been associated with autoimmunity. Here, we have identified a homozygous missense mutation in the gene encoding the base excision repair enzyme Nei endonuclease VIII-like 3 (NEIL3) that abolished enzymatic activity in 3 siblings from a consanguineous family. The NEIL3 mutation was associated with fatal recurrent infections, severe autoimmunity, hypogammaglobulinemia, and impaired B cell function in these individuals. The same homozygous NEIL3 mutation was also identified in an asymptomatic individual who exhibited elevated levels of serum autoantibodies and defective peripheral B cell tolerance, but normal B cell function. Further analysis of the patients revealed an absence of LPS-responsive beige-like anchor (LRBA) protein expression, a known cause of immunodeficiency. We next examined the contribution of NEIL3 to the maintenance of self-tolerance in Neil3–/– mice. Although Neil3–/– mice displayed normal B cell function, they exhibited elevated serum levels of autoantibodies and developed nephritis following treatment with poly(I:C) to mimic microbial stimulation. In Neil3–/– mice, splenic T and B cells as well as germinal center B cells from Peyer's patches showed marked increases in apoptosis and cell death, indicating the potential release of self-antigens that favor autoimmunity. These findings demonstrate that deficiency in NEIL3 is associated with increased lymphocyte apoptosis, autoantibodies, and predisposition to autoimmunity.
GW27-e0356 Effects of low-level vagus nerve stimulation on ventricular electrophysiological properties in acute myocardial ischemia-reperfusion injury canines
Authors: Chen Mingxian, Lilei Yu, Qiming Liu, Zhuo Wang, Songyun Wang, Liping Zhou, Hong Jiang, Shenghua Zhou
Journal: Journal of the American College of Cardiology (2016)
Intrahepatic Portal Application of Autologous CD133+ Bone Marrow Stem Cells to the Liver - Early Experience with a Novel Concept To Support Hepatic Regeneration.
Authors: Jan Schulte am Esch, Wolfram T. Knoefel, Michael Klein, Alireza Ghodsizad, Guenter Fuerst, Ludger W. Poll, Andreas Saleh, Christoph Piechaczek, Nico Feifel, Marcus Stockschlaeder, Volker Stoldt, Nikolas Stoecklein, Roy Y. Tustas, Claus F. Eisenberger, Matthias Peiper, Dieter Haeussinger, Stefan B. Hosch
Journal: Blood (2004)
Validation of late oral health outcomes, an oral health subscale of the Vanderbilt Head and Neck Symptom Survey in post-radiation therapy head and neck cancer patients.
Authors: Leanne Kolnick, Jie Deng, Joel Brian Epstein, Cesar A. Migliorati, Julie Rezk, Mary S. Dietrich, Barbara A. Murphy
Journal: Journal of Clinical Oncology (2013)

6040 Background: The Vanderbilt Head and Neck Symptom Survey (VHNSS) version 2.0 oral symptom subscale was developed to address potentially overlooked and underreported oral health issues. We report the validation of questions pertaining to xerostomia (4 items), dental health (4 teeth), dentures (1 item) and trismus (1 item). Methods: Between May 2011 and April 2012, 50 patients treated with chemoradiotherapy for head and neck cancer completed the 50-item VHNSS survey, underwent an oral health assessment by a dentist, salivary flow and inter-incisal opening (IIO) measurements. Results: Patient reported “problems with dry mouth” correlated with unstimulated salivary flow rates (-0.43, p = 0.002). “Cracked teeth” (-0.55, p = &lt; 0.001) or “difficulty chewing due to teeth” (-0.43, p = 0.004) correlated with urgent or emergent dental care issues identified on exam. Using a cut off of &gt;4 on any of four the dental questions, we were able to identify 83% of patients with urgent or emergent dental issues. The ROC curve was useful (0.89, p&lt; 0.001) for separating patients with and without urgent/emergent dental issues. “Limitations” in jaw movement correlated with IIO (-0.43, p = 0.002). Small numbers of patients with dentures precluded meaningful analysis of this subsample. Conclusions: Clinically significant oral health issues pertaining to xerostomia, dental health and trismus may be identified using the oral health subscale of the VHNSS version 2.0. Patients who score &gt; 4 on any of the teeth related items should be referred for immediate dental evaluation; and for trismus should be referred for physical therapy.
Orthostatic hypotension linked to risk of dementia, finds study
Authors: Susan Mayor
Journal: BMJ (2016)

Orthostatic hypotension is associated with a 15% rise in long term risk of dementia, including Alzheimer’s disease, a follow-up study has found.

Orthostatic hypotension affects 20-30% of elderly people and is a common cause of transient cerebral hypoperfusion. The study investigated the future risk of dementia in people with orthostatic hypotension, defined as ≥20 mm Hg drop in systolic blood pressure or ≥10 mm Hg drop in diastolic blood pressure within three minutes of standing up after lying down for five …